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Abstract
Background: Multiple gated acquisition scanning (MUGA) is a common imaging modality for baseline and serial
assessment of left ventricular ejection fraction (LVEF) for cardiotoxicity risk assessment prior to, surveillance during,
and surveillance after administration of potentially cardiotoxic cancer treatment. The objective of this study was to
compare the accuracy of left ventricular ejection fractions (LVEF) obtained by contemporary clinical multiple gated
acquisition scans (MUGA) with reference LVEFs from cardiovascular magnetic resonance (CMR) in consecutive
patients with cancer.
Methods: In a cross-sectional study, we compared MUGA clinical and CMR reference LVEFs in 75 patients
with cancer who had both studies within 30 days. Misclassification was assessed using the two most common
thresholds of LVEF used in cardiotoxicity clinical studies and practice: 50 and 55%.
Results: Compared to CMR reference LVEFs, MUGA clinical LVEFs were only lower by a mean of 1.5% (48.5% vs. 50.0%,
p = 0.17). However, the limits of agreement between MUGA clinical and CMR reference LVEFs were wide at −19.4 to 16.
5%. At LVEF thresholds of 50 and 55%, there was misclassification of 35 and 20% of cancer patients, respectively.
Conclusions: MUGA clinical LVEFs are only modestly accurate when compared with CMR reference LVEFs. These data
have significant implications on clinical research and patient care of a population with, or at risk for, cardiotoxicity.
Keywords: Cardiovascular magnetic resonance, MUGA, Cancer, Ejection fraction, Onco-cardiology, Cardio-oncology
Background
Common cancer treatments such as anthracyclines and
trastuzumab are associated with an increased risk of car-
diotoxicity, which is responsible for significant mortality
and morbidity in cancer survivors [1, 2]. Assessment of
left ventricular ejection fraction (LVEF) has been, and
continues to be the most widely used method for cardio-
toxicity risk assessment prior to, surveillance during,
and surveillance after administration of potentially cardi-
otoxic cancer treatment [3].
Since the 1970s [4], multiple gated acquisition scan-
ning (MUGA) has been one of the first-line imaging
modalities for baseline and serial assessment of LVEF for
cardiotoxicity. In addition to concerns about exposure to
ionizing radiation, there is concern that contemporary
gamma cameras may not allow optimal patient position-
ing for LVEF assessments [3]. Thus, it is possible that
contemporary MUGA in cancer patients may not pro-
vide accurate estimates of LVEFs. Inaccurate LVEF
assessment may carry significant implications for the
care of cancer patients receiving potentially cardiotoxic
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treatment since LVEFs play an important role in deci-
sions to start, continue, hold or stop such treatment.
The objective of this study was to compare the accur-
acy of LVEFs obtained by contemporary clinical MUGA
in consecutive patients with cancer with reference LVEFs
from cardiovascular magnetic resonance (CMR), the
gold standard technique for assessment of left ventricu-
lar volumes and LVEF [5].
Methods
Patients and data collection
The study sample consisted of consecutive patients with
cancer who had both MUGA and CMR within 30 days be-
tween January 2007 and September 2016 at the University
of Minnesota Medical Center, Minneapolis, Minnesota,
USA. The institutional MUGA database was cross-matched
with the University of Minnesota Cardiovascular Magnetic
Resonance Registry, an ongoing observational registry
including all patients that undergo CMR at the University
of Minnesota, to identify the study patients. Patients were
excluded if their records indicated any of these interven-
ing clinical events that could potentially impact cardiac
function: acute myocardial infarction, heart failure
hospitalization, administration of potentially cardiotoxic
cancer treatment, or acute systemic illness such as sep-
sis. An electronic database was created to include
demographic information, medical history including
reasons for the studies, co-morbidities and medications,
and MUGA and CMR findings for each patient. This
retrospective cross-sectional study was approved by
University of Minnesota’s Institutional Review Board
with a waiver of informed consent.
Multiple-gated acquisition scanning (MUGA)
MUGA scans were performed per standard recommen-
dations to determine LVEF [6, 7] before or after cancer
treatment. The UltraTag RBC kit (Mallinckrodt, Inc., St.
Louis, Missouri, USA) was used. Erythrocyte labeling
was performed using modified in vitro method with
technetium 99 m-labeled red blood cells with an activity
of approximately 11 to 13 MBq/kg. Images were ac-
quired with a Siemens e-cam dual-head gamma camera
(Siemens, Erlangen, Germany) equipped with a parallel
hole, low energy high-resolution collimator, with energy
window of 15% symmetrically placed over a photopeak
of 140 keV. Data were acquired in electrocardiogram-
synchronized frame mode using 24 frames per cardiac
cycle, with 128 × 128 matrix of 16-bit pixels. Acquisition
times were adjusted to achieve a minimum of 200,000
counts per frame. Patients were resting and supine, and
the best septal view was individually adjusted from 45°
left anterior oblique position with 10°–15° caudal tilt.
Experienced nuclear medicine technologists performed
LVEF analyses. Scintigrams were smoothed off-line using
standard algorithms, and background correction was
performed. The LV regions of interest, as well as back-
ground activity, were selected automatically by the com-
puter program (E. Soft; Siemens Medical Solutions,
Erlangen, Germany) with manual correction by the inter-
preting technologists as necessary. Left ventricular time-
activity curves were constructed, and LVEF was calculated
as ([background-corrected end-diastolic counts − back-
ground-corrected end-systolic counts])/(background-cor-
rected end-diastolic counts) × 100. Since our aim was to
evaluate “real-world” MUGA data, clinically reported
LVEFs were used by design, and analyses were not re-
peated for this study.
Cardiovascular magnetic resonance (CMR)
CMR was performed on clinical 1.5 T Siemens scanners
(Avanto and Aera) using phased-array receiver coils ac-
cording to standard recommendations [8, 9]. A typical
protocol was as follows: First, localizers were acquired to
identify the cardiac position, and the standard long- and
short-axes of the heart, and then cine images were ac-
quired in multiple short-axis (every 10 mm to cover the
entire LV from the mitral valve plane through the apex)
and three long-axis views (2, 3, and 4 chamber) using a
steady-state free-precession (SSFP) sequence (repetition
time msec/echo time ms, 3.0/1.5; temporal resolution,
35–40 ms; slice thickness, 6 mm; inter-slice gap, 4 mm;
flip angle, 60°; in-plane resolution, approximately
1.6 mm × 1.6 mm). Other sequences, including perfu-
sion and delayed-enhancement imaging were per-
formed as clinically indicated.
The LVEF was determined by quantitative analysis ac-
cording to standard recommendations [10]. To allow use
as a reference standard, all CMRs were re-analyzed,
blinded to MUGA and clinical data, by a single investi-
gator (C.S.) with 9 years of experience in CMR. Short-
axis cine images were used for manual tracing of LV
endocardial and epicardial contours at end-diastole and
end-systole. Papillary muscles were excluded from the
LV myocardial mass (i.e., included in the LV blood
volume) to match the methodology used in MUGA.
This is an acceptable approach [10], allowing quicker
quantitative analyses [11] and is more practical in the
routine clinical setting. The LVEF was calculated as
([LV end-diastolic volume − LV end-systolic volume])/
(LV end-diastolic volume) × 100.
Statistical analysis
Statistical analyses were performed on Stata version 13
(StataCorp LP, College Station, Texas, USA). Continuous
variables were expressed as means and standard devia-
tions, or medians and inter-quartile ranges (IQR) for
data that were not normally distributed. MUGA clinical
and CMR reference LVEFs were compared using
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Student’s paired t-test, Bland-Altman analysis and Lin’s
concordance correlation coefficient [12]. Lin’s concord-
ance correlation coefficient (rc) provides a measure of
reliability based on covariation and correspondence, un-
like Pearson’s correlation coefficient (r) that provides a
measure of linear covariation without accounting for the
degree of correspondence between the two sets of
values. Pearson’s correlation coefficient (r) was used to
examine the correlation between the time interval be-
tween the two studies and differences between MUGA
and CMR LVEFs. We studied the two most common ab-
solute thresholds of LVEF used in cardiotoxicity clinical
studies and practice: 50 and 55% [13]. The kappa statis-
tic was used to assess agreement between MUGA and
CMR classification of normal vs. abnormal LVEFs.
Kappa values were interpreted as widely accepted in the
literature [14] – a kappa value of <0 would be consid-
ered as less than chance agreement, between 0.01 and
0.20 as slight agreement, between 0.21 and 0.40 as fair
agreement, between 0.41 and 0.60 as moderate agree-
ment, between 0.61 and 0.80 as substantial agreement,
and between 0.81 and 0.99 as almost perfect agreement.
Logistic regression was used to determine univariate
predictors of misclassification. All statistical comparisons
were two tailed, and a p value less than 0.05 was consid-
ered to indicate statistical significance.
Results
Study sample
Eighty patients were identified as having had MUGA
and CMR within 30 days of each other, of which 77 were
cancer patients. Two patients received potentially cardi-
otoxic cancer treatment between MUGA and CMR and
were excluded from the study. The remaining 75 pa-
tients formed the study cohort. Patient characteristics
are listed in Table 1.
All MUGAs were performed for assessment of LVEF
prior to, or after potentially cardiotoxic cancer treatment.
CMRs were performed for characterization of cardiomy-
opathy noted on a prior imaging study (69%), evaluation
of suspected obstructive coronary artery disease (15%),
evaluation of suspected infiltrative cardiomyopathies
(12%), abnormal electrocardiogram (3%), and in one case,
evaluation of a suspected intracardiac mass (1%).
Comparisons between MUGA and CMR LVEFs
There was a median of 8 days (interquartile range 5,
10 days) between MUGA and CMR studies. In 62 (83%)
patients, the studies were performed within 15 days of
each other. MUGA was performed at least a day be-
fore CMR in 69 (92%) patients, the two studies were
performed the same day in two (3%) patients, and
MUGA was performed after CMR in the remaining
four (5%) patients.
The mean MUGA LVEF was not significantly different
when compared with the mean CMR LVEF (48.5% vs.
50.0%, p = 0.17). However, the random error between
MUGA and CMR LVEFs was substantial, as evidenced
by the Bland-Altman 95% limits of agreement (−19.4,
16.5) (Fig. 1). In 42 (56%) patients, the MUGA LVEF
was lower than the CMR LVEF.
The Lin’s concordance correlation coefficient (rc) was
0.63. Using the cutoffs proposed by McBride [15], this in-
dicates poor agreement between MUGA and CMR LVEFs.
There was no correlation between the time interval
between MUGA and CMR and the absolute difference
between MUGA and CMR LVEFs (r = −0.20, p = 0.08),
or the time interval between the two studies and
whether MUGA LVEF was higher or lower than CMR
LVEF (r = 0.05, p = 0.65).
Using a LVEF threshold of 50%, there was misclassifi-
cation of 26 of 75 (35%) patients between normal and
abnormal categories (Table 2 and Fig. 2) – 19 patients
that had MUGA LVEF <50% had a CMR LVEF ≥50%,
and seven patients that had MUGA LVEF ≥50% had
Table 1 Characteristics of study sample
Age, years 58 ± 12
Male sex 44 (59%)
Body mass index, kg/m2 29.5 (26.1, 33.2)
Body surface area, m2 2.2 (2.0, 2.4)
Cancer type
Breast cancer 7 (9%)
Leukemia 23 (31%)
Lymphoma 22 (29%)
Multiple myeloma 13 (17%)
Myelodysplastic syndrome 8 (11%)
Sarcoma 2 (3%)
History of atrial fibrillation 14 (19%)
Left bundle branch block 3 (4%)
Hematocrit at the time of MUGA, % 33.0 ± 5.4
Serum creatinine at the time of MUGA, mg/dL 1.0 ± 0.7
Heart rate during MUGA, beats/min 76.9 ± 14.4
MUGA radioisotope dose, mCi 26.2 ± 1.7
MUGA LVEF, % 48.5 ± 11.5
Interval between MUGA and CMR, days 8.0 (5.5, 10.0)
CMR LV end diastolic volume, mL 167 ± 45
CMR LV end diastolic volume, indexed (mL/m2) 76.6 ± 20.0
CMR LV mass, g 121 ± 28
CMR LV mass, indexed (g/m2) 55.3 ± 11.6
CMR regional LV dysfunction 6 (8%)
CMR LVEF, % 50.0 ± 9.9
Data are presented as mean ± SD, n (%), or median (interquartile range), unless
otherwise indicated
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CMR LVEF <50%. Thus, MUGA LVEFs only had fair
agreement with CMR LVEFs (kappa = 0.31).
Next, using a LVEF threshold of 55%, there was mis-
classification of 15 of 75 (20%) patients between normal
and abnormal categories (Table 2 and Fig. 2) – 12 pa-
tients that had MUGA LVEF <55% had a CMR LVEF
≥55%, and three patients that had MUGA LVEF ≥55%
had CMR LVEF <55%. MUGA LVEFs had a moderate
agreement with CMR reference LVEFs (kappa = 0.54).
Figure 3 shows MUGA and CMR images from two
study patients with misclassification between MUGA
and CMR LVEFs.
Predictors of misclassification
On univariate logistic regression analysis, the only sig-
nificant predictor of misclassification at the 50% LVEF
threshold was the indexed LV end-diastolic volume
(Table 3). At the 55% LVEF threshold, significant predic-
tors of misclassification were indexed LV end-diastolic
volume, atrial fibrillation and hematocrit (Table 3). Thus,
a smaller indexed LV end-diastolic volume was a pre-
dictor of misclassification at both thresholds for a nor-
mal LVEF of ≥50% and ≥55%.
Discussion
Using a sample of cancer patients that had both MUGA
and CMR performed within 30 days, we found that
MUGA LVEFs were only modestly accurate when com-
pared with reference LVEFs by CMR, the gold standard
technique for the assessment of LVEF. MUGA LVEFs
were systemically lower by 1.5%, suggesting only a small
mean discordance between the two methods. However,
the limits of agreement between MUGA and CMR
LVEFs were wide (−19 to 16%). This suggests large indi-
vidual discordance, or in other words, low accuracy for
MUGA LVEFs when compared to CMR LVEFs. Further-
more, using LVEF thresholds of ≥50% and ≥55% to
define normal, there was misclassification between
MUGA and CMR LVEFs in categorizing 35 and 20% of
patients respectively.
Schwartz et al. in 1987 demonstrated in patients re-
ceiving doxorubicin that LVEF estimates by MUGA used
per their proposed guidelines reduced the incidence and
severity of clinical congestive heart failure [16]. Normal
LVEF was defined as ≥50%, and cardiotoxicity was de-
fined as an absolute decrease in LVEF of ≥10% with a
final LVEF of ≤50% [16]. These data, along with data
demonstrating high reproducibility [17] and low variabil-
ity [18], established MUGA as the modality of choice for
serial testing of LVEF in patients with cancer. However,
validation of the accuracy of MUGA in these studies was
done with comparisons to contrast left ventriculography
[19], which has significant variability [20], and is argu-
ably a poor reference standard. In a phantom study com-
paring CMR, MUGA, and left ventriculography, left
ventriculography was the least accurate, and MUGA was
less accurate than CMR [21]. Of note, CMR in this study
was performed using a gradient-echo sequence, which
has lower blood-to-myocardium contrast [22], accuracy
and reproducibility than the currently used SSFP sequence
Fig. 1 Comparison of MUGA and CMR LVEFs. a Bland-Altman plot with limits of agreement and b Scatterplot
Table 2 Performance of MUGA LVEFs compared with CMR







False-negative rate 19% 6%
False-positive rate 49% 43%
Positive predictive value 60% 79%
Negative predictive value 74% 84%
Accuracy (correct classification) 65% 80%
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[23]. Furthermore, in an in vitro model, LV volumes by
CMR have been shown to be highly accurate when com-
pared to volumes obtained using latex casts of excised
human LVs [24].
The systematic bias between CMR and MUGA LVEFs
has been variable in the literature [5, 25, 26]. The
discrepancies are likely due to differences between in-
stitutions in imaging and analysis techniques, and
software. Audits of MUGA LVEFs in the United Kingdom,
Australia and New Zealand have demonstrated signifi-
cant variability between centers, mainly due to differ-
ences in the software used for LVEF analyses [27, 28].
The systemic bias between mean MUGA and CMR
LVEFs in this study is overshadowed by the substan-
tial random error when comparing the two modalities.
Possible sources of inaccuracy associated with MUGA
include suboptimal patient positioning with current
gamma cameras, limited spatial resolution, the need
for background correction, errors from overlapping struc-
tures, and gating inaccuracies due to arrhythmias.
Our findings are in contrast with those of Walker et al.
[29] who studied 50 consecutive patients with breast can-
cer prior to adjuvant trastuzumab, at 6 and 12 months
and found a strong correlation (r of 0.88, 0.97 and 0.87 at
baseline, 6 and 12 months respectively) between MUGA
and CMR. It could be argued that this study was not
reflective of real-life practice as demonstrated by the
exclusion of patients with a history of atrial fibrillation or
intraventricular conduction delay. Although consecutive
patients were enrolled in the study, a majority had LVEF
<55% at baseline (prior to trastuzumab therapy) and pro-
ceeded to receive trastuzumab. Additionally, whether
MUGA and CMR LVEF analyses were blinded to the re-
sults of the other imaging technique was not stated.
Fig. 2 Misclassification of MUGA LVEFs. a Threshold of 50% and b Threshold of 55%
Fig. 3 MUGA and CMR images from example study patients with misclassification of MUGA LVEFs. a and b are end-diastolic and end-systolic
MUGA images respectively from a patient whose LVEF was analyzed at 47.0%, c and d are end-diastolic and end-systolic CMR images respectively
from the same patient acquired 4 days later, with LVEF analyzed at 55.2%. e and f are end-diastolic and end-systolic MUGA images respectively
from a patient whose LVEF was analyzed at 69.2%, g and h are end-diastolic and end-systolic CMR images respectively from the same patient
acquired 7 days later, with LVEF analyzed at 44.0%
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Early MUGA studies in the 1970s and 1980s were per-
formed using small-field-of-view, single-headed gamma
cameras that allowed optimal positioning of the patient
to obtain the best separation between the left and the
right ventricles. Current gamma cameras are predomin-
antly large-field-of-view, dual-headed systems that do
not permit this degree of patient positioning [3].
We attempted to identify potential associations for
misclassification between MUGA and CMR LVEFs in
our cohort. Smaller LV size was a significant predictor of
misclassification, which we speculate is a consequence of
differences in spatial resolution between the two mo-
dalities. Smaller hearts may have less accurate LVEF
measurements by MUGA due to its relatively lower
spatial resolution. The presence of arrhythmias may
have also contributed to discrepancies between the
two imaging modalities, as a history of atrial fibrilla-
tion was a significant predictor of misclassification at
the higher LVEF threshold.
Our findings have important implications for clinical
investigations and the care of patients receiving poten-
tially cardiotoxic cancer treatment. MUGA is frequently
used in these patients; in a study of 2203 patients
66 years or older who received trastuzumab for adjuvant
treatment of breast cancer, 28% had baseline and serial
assessment of LVEF with MUGA alone, and 23% with a
combination of MUGA and echocardiography [30]. Im-
portant therapeutic decisions are often based on the
LVEF in patients with cancer. Imprecise LVEFs leading
to incorrect classification of patients as normal or abnor-
mal may lead to erroneous decisions about the choice of
standard-of-care treatment, or less cardiotoxic – but po-
tentially less effective – alternatives such as reduced
doses of standard chemotherapy regimens or nonstan-
dard regimens. Similarly, they may influence incorrect
decisions regarding the frequency of clinical follow up,
screening by imaging to detect cardiotoxicity, and treat-
ment with cardiac medications for the cardiomyopathy.
Ultimately, erroneous classification of patients as nor-
mal or abnormal due to inaccurate LVEFs may result
either in cardiomyopathy and heart failure that could
potentially have been prevented, or lower treatment
response and worse cancer outcomes from less effect-
ive cancer treatment used in response to unwarranted
concerns for cardiotoxicity.
MUGA involves the use of ionizing radiation in a pa-
tient population that requires serial studies. Guidelines
for cardiac monitoring after trastuzumab treatment rec-
ommend the use of the same imaging modality through-
out the course of treatment [31, 32]. A breast cancer
patient receiving adjuvant trastuzumab is recommended
to have LVEF assessment before starting treatment,
every 3 months during, upon completion of treatment,
and every 6 months for at least 2 years following com-
pletion of treatment [33]. More frequent monitoring is
recommended if trastuzumab is withheld for a signifi-
cant drop in LVEF [33]. With 12 months of adjuvant
trastuzumab as the standard of care, this translates into
a minimum of nine studies. With an average typical
effective ionizing radiation dose of 8 mSv per MUGA
[34, 35], the use of MUGA would result in a significant
dose of ionizing radiation with associated risks of radiation-
related secondary cancers [36, 37]. A recent publication
highlighted this issue through the case of a patient with
multiple myeloma who received 17 MUGAs, corresponding
to an effective radiation dose of 113 mSv, over a span of 3
years [38]. A scientific statement from the American Heart
Association on approaches to enhancing radiation safety in
cardiovascular imaging carries the recommendation that
when a cardiac imaging study is indicated, a comparable
test with similar accuracy, cost and convenience, which
does not use ionizing radiation, should be preferred [39].
Table 3 Predictors of misclassification of MUGA LVEFs between normal and abnormal categories compared with CMR LVEFs
Variable LVEF threshold of 50% LVEF threshold of 55%
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Male sex 0.94 (0.36–2.47) 0.90 1.07 (0.34–3.40) 0.91
Body mass index 1.03 (0.95–1.12) 0.50 1.07 (0.96–1.18) 0.22
History of atrial fibrillation 1.54 (0.47–5.03) 0.48 4.33 (1.21–15.48) 0.02
Left bundle branch block 0.94 (0.08–10.88) 0.96 - -
Heart rate during MUGA 0.98 (0.95–1.01) 0.26 0.99 (0.95–1.03) 0.54
Hematocrit at the time of MUGA 1.08 (0.99–1.19) 0.10 1.16 (1.02–1.32) 0.02
Serum creatinine at the time of MUGA 0.34 (0.06–2.06) 0.24 0.48 (0.07–3.26) 0.46
Time interval between MUGA and CMR 0.99 (0.93–1.06) 0.79 0.98 (0.90–1.07) 0.64
CMR LV end diastolic volume, indexed 0.97 (0.94–0.99) 0.03 0.96 (0.92–0.99) 0.04
CMR LV mass, indexed 0.98 (0.94–1.03) 0.46 0.98 (0.93–1.03) 0.43
CMR regional LV dysfunction 0.35 (0.04–3.18) 0.35 - -
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Echocardiography and CMR are alternatives that do not
involve ionizing radiation. However, two-dimensional echo-
cardiography has been shown to have limited performance
compared to CMR for the detection of cardiotoxicity in
adult survivors of childhood cancer for cardiomyopathy
[40]. Unlike MUGA, CMR provides additional clinically
valuable information including assessments of right ven-
tricular (RV) size and function, atrial size and function,
valvular disease, pericardial disease, intracardiac thrombus
and extracardiac pathology. In our study, CMR revealed
that 80% of patients had at least one additional abnormality:
52% had RV dysfunction (defined as RVEF <50%), 33% had
an enlarged left atrium, 12% had an enlarged right atrium,
13% had significant valvular disease, 9% had a pericardial
effusion, 11% had pleural effusions, 5% had an intracardiac
thrombus, and 3% had cardiac tumors. Additionally, late
gadolinium enhancement CMR has the ability to detect the
presence and patterns of fibrosis, which would help identify
the etiology for cardiomyopathy [41] in cancer patients. T1
mapping is a newer CMR technique for the detection of
diffuse myocardial disease, that holds significant promise in
the prediction, early detection and prognostication of cardi-
otoxicity [42]. Thus, findings on CMR other than the LVEF
may have significant impact on management and clinical
decision-making [43].
Limitations
Our findings must be interpreted in the context of the
study design. Rather than to perform a head-to-head
comparison of two imaging modalities, our aim was to
examine the accuracy of real world, clinical LVEFs by
MUGA, which oncologists and cardiologists use every
day in clinical practice to make important decisions. To
achieve this, we compared clinically analyzed MUGA
LVEFs with CMR LVEFs that were ascertained by a sin-
gle blinded expert investigator for this study. This design
allowed comparison of real world MUGA LVEFs to ar-
guably the most accurate estimates possible, of the true
LVEF (since even a necropsy cannot provide a LVEF).
Since MUGA and CMR studies were not performed
on the same day in all cases except one, there is a possi-
bility of true LVEF changes in the interim period. We
limited this possibility by excluding patients with clinical
events and potentially cardiotoxic treatment during or in
the time interval between the two studies. Additionally,
we did not find correlations between the time interval
between the two techniques and the absolute difference
in LVEFs, whether MUGA clinical LVEF was higher or
lower than CMR reference LVEF, or whether there was
misclassification between normal and abnormal categories.
While making clinical decisions on the management
of cardiotoxicity, the change in LVEF is often used in
conjunction with the absolute LVEF. We did not in-
vestigate changes in LVEF in this study. Finally, this
is a relatively small, single-center study subject to re-
ferral bias.
Conclusions
MUGA LVEFs are only modestly accurate when com-
pared with reference LVEFs from CMR. At LVEF thresh-
olds of 50 and 55%, there is misclassification of 35 and
20% of cancer patients, respectively, to either normal or
abnormal categories. Given the significant implications
of these hypothesis-generating data on clinical research
and patient care of a population with, or at risk for, cardio-
toxicity, prospective comparisons of MUGA with CMR for
the management of cancer patients are urgently warranted.
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